SOURCE: Equity News Circuit

Equity News Circuit

April 16, 2013 08:20 ET

Free Research Reports on HCA, KWK, SCHW and THRX Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - Apr 16, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

HCA Holdings Inc. (NYSE: HCA) shares declined 4.18 percent on volume of 4.65 million shares traded Monday to close at $36.72 a share. The company announced that revenues for the first quarter of 2013 are expected to be approximately $8.440 billion compared to $8.405 billion in the first quarter of 2012.

Find out more about HCA Holdings including full access to the free equity report at: www.ParagonReport.com/HCA

Quicksilver Resources Inc. (NYSE: KWK) shares declined 10.36 percent on volume of 4.0 million shares traded Monday to close at $2.51 a share. Energy stocks fell sharply Monday as oil futures declined 3 percent to close at its lowest level of the year after China reported gross domestic product increase just 7.7 percent in the first quarter, down from growth of 7.9 percent in the previous quarter.

Find out more about Quicksilver Resources including full access to the free equity report at: www.ParagonReport.com/KWK

Charles Schwab Corp. (NYSE: SCHW) shares declined 3.82 percent on volume of over 10.5 million shares traded Monday to close at $16.62 a share. The company reported net income of $206 million for the first quarter of 2013, a decrease of 3 percent from the previous quarter, and an increase of 6 percent from the year ago quarter.

Find out more about Charles Schwab including full access to the free equity report at: www.ParagonReport.com/SCHW

Theravance Inc. (NASDAQ: THRX) shares surged 19.36 percent on volume of 4.74 million shares traded Monday to close at $28.36 a share. The FDA has released positive results from a review of Theravance's and partner GlaxoSmithKline's experimental inhaler drug, Breo Ellipta.

Find out more about Theravance including full access to the free equity report at: www.ParagonReport.com/THRX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information